The stock is listed on the Nasdaq Global Select Market

Davis Polk advised the joint book-running managers in connection with the upsized initial public offering of 34,500,000 shares of common stock of ACELYRIN, INC. at $18 per share for total gross proceeds of $621 million. The shares sold include 4,500,000 shares sold pursuant to the underwriters’ over-allotment option. The common stock is listed on the Nasdaq Global Select Market under the symbol “SLRN.”

ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring and accelerating the development and commercialization of transformative medicines.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Rebecca Lei.  Partner David R. Bauer and associates Adrian Rabin, Emma C. Himes and Anthony Tran provided intellectual property advice. The tax team included counsel Christopher A. Baratta and associate Eitan Ulmer. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.